Diabetes mellitus does not play a major role in survival from renal cell carcinoma (RCC), according to data presented at the 22nd annual meeting of the Society of Urologic Oncology.
“Diabetes mellitus has been hypothesized to be a risk factor for development of renal cell carcinoma,” Ava Saidian, MD, of the University of California, San Diego, explained.
To test this theory, her team retrospectively analyzed survival outcomes from 2927, 2513, and 460 patients with stage 1, 2, and 3 RCC, respectively, from the International Marker Consortium for Renal Cancer (INMARC). Of these groups, 24%, 27%, and 77% had diabetes, respectively.
According to Kaplan Meier analyses, diabetes status had no significant relationship with cancer-specific mortality or progression-free survival at any RCC stage, Dr Saidian reported. Only patients without diabetes mellitus had significantly increased risks of all-cause mortality in stage 1 and 3 RCC, a Cox Regression multivariable analysis showed.
Tumor size, male sex, and hypertension were significantly associated with 1.1-, 1.4-, and 1.7-fold increased risks for all-cause mortality, respectively.
“Our findings suggest that [diabetes mellitus] may have impact on survival in RCC, but this impact is mostly driven by non-oncologic as opposed to oncologic effects,” Dr Saidian concluded.
Saidian A, Walia A, Patil D, et al. Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: a multi-center analysis? Presented at the 22nd annual meeting of the Society of Urologic Oncology. December 1-3, 2021. Poster 24.
This article originally appeared on Renal and Urology News